CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target
Advanced Science · 2026-02 · 13 (8)
DOI: 10.1002/advs.202518884 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 27.12.2025. Verfasst von Xiang-Min Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, National Translational Science Center for Molecular Medicine, The Fourth Military Medical University, Xi'an, Shaanxi, 710…. Hauptthemen laut MEDLINE: Basigin. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 260 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shaanxi Natural Science Foundation.
Abstract (Originalsprache)
CD147 (Basigin/EMMPRIN), a multifunctional member of the immunoglobulin superfamily (IgSF), is a critical regulator of tumor progression, immune modulation, and metabolic adaptation. Under physiological conditions, it acts as a dynamic scaffold, interacting with monocarboxylate transporters (MCTs), integrins, and cyclophilin A (CyPA) to orchestrate spermatogenesis, embryo implantation, and neural network function. Pathological overexpression of CD147 induces the secretion of matrix metalloproteinases (MMPs), epithelial‐mesenchymal transition (EMT), metabolic reprogramming, and immune evasion, functioning as an independent prognostic biomarker in multiple malignancies. Beyond oncology, CD147 is exploited as an entry receptor for pathogens, including SARS‑CoV‑2, HIV‑1, Plasmodium falciparum , and contributes mechanistically to cardiovascular, autoimmune, and neurodegenerative diseases. Notably, CD147 acts as a fundamental “Energy‐Structure Coupler,” coordinating metabolic flux (via MCTs) with morphogenetic plasticity (via integrins/MMPs) to maintain cellular homeostasis. This review summarizes current insights into CD147's molecular structure, isoforms, post‐translational modifications, and signaling pathways, highlighting its pivotal roles across cancer, infection, autoimmunity, and cardiovascular disease. Finally, we discuss challenges such as the “specificity paradox” and propose emerging strategies to exploit CD147 as a precision biomarker and therapeutic target across diverse diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology, National Translational Science Center for Molecular Medicine, The Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
- State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, Shaanxi, 710032, China.
ORCID-Profile: Xiang-Min Yang, Huijie Bian, Zhi-Nan Chen
Förderung
- National Natural Science Foundation of China
- Shaanxi Natural Science Foundation
Zitieren
APA
Yang, X. M., Bian, H., & Chen, Z. N. (2026). CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target. Advanced Science, 13(8). https://doi.org/10.1002/advs.202518884
Vancouver
Yang XM, Bian H, Chen ZN. CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target. Advanced Science. 2026;13(8). doi:10.1002/advs.202518884
BibTeX
@article{Yang2026,
author = {Yang, Xiang-Min and Bian, Huijie and Chen, Zhi-Nan},
title = {CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {8},
doi = {10.1002/advs.202518884}
}
EUVIMED